bluebird bio to Present New Data from Novel Anti-BCMA CAR T Cell Therapy bb2121 at EORTC-NCI-AACR Molecular Targets and Cancer Therapies Symposium

On November 14, 2016 bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, reported that interim data from its study of bb2121, the company’s anti-BCMA CAR T cell therapy, currently in a Phase 1 trial of patients with relapsed/refractory multiple myeloma will be presented at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Molecular Targets and Cancer Therapies Symposium in Munich, Germany (Press release, bluebird bio, NOV 14, 2016, View Source;p=RssLanding&cat=news&id=2222159 [SID1234516581]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma

Date: Thursday, December 1, 2016, 17:40 CET (11:40 am ET)
Session: Plenary Session 7

Argos Therapeutics Reports Third Quarter 2016 Financial Results and Recent Operational Highlights

On November 14, 2016 Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, reported financial results for the third quarter ended September 30, 2016 and reported on the company’s corporate and operational highlights (Press release, Argos Therapeutics, NOV 14, 2016, View Source [SID1234516560]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During the third quarter, we further strengthened our management team and financial position," said Jeff Abbey, president and chief executive officer. "As we previously announced, Dr. Richard Katz joined us as chief financial officer in July. Rich has already played an instrumental role by driving the most recent financing, in which we raised gross proceeds of $50 million. In addition, he has initiated the transformation of our finance structure towards that of a commercial stage company."

"Our Phase 3 ADAPT study of AGS-003 in advanced renal cell carcinoma continues to progress and we look forward to the next Independent Data Monitoring Committee meeting in February, followed by anticipated top-line data in the first half of 2017," Mr. Abbey stated. "In addition, in July the first patient was dosed in Stage 2 of the investigator-initiated adult HIV eradication trial of AGS-004 in combination with the latency reversing drug vorinostat being conducted at the University of North Carolina, Chapel Hill. This is the first clinical trial evaluating the ‘kick and kill’ approach employing an HIV latency-reversing drug combined with an individualized immunotherapy. This is an exciting step, as it represents another promising opportunity to demonstrate the versatility of our Arcelis platform technology."

Third Quarter 2016 and Recent Operational Highlights:

In July 2016, Richard D. Katz, MD, joined the company as chief financial officer
In July 2016, the first patient was dosed in Stage 2 of the investigator-initiated adult HIV eradication trial of AGS-004
In August 2016, the company completed an equity financing with gross proceeds of $50 million
Selected Third Quarter 2016 Financial Results

Net loss for the three months ended September 30, 2016 was $12.2 million, or $0.32 per share, compared to a net loss of $20.1 million, or $0.97 per share, for the same period in 2015. Net loss for the nine months ended September 30, 2016 was $37.7 million, or $1.30 per share, compared to a net loss of $57.2 million, or $2.81 per share, for the same period in 2015.

Revenue for the three months ended September 30, 2016 totaled $0.1 million compared to $0.2 million for the same period in 2015. Revenue for the nine months ended September 30, 2016 totaled $0.8 million compared to $0.4 million for the same period in 2015.

Research and development expense for the three months ended September 30, 2016 totaled $9.3 million compared to $17.2 million for the same period in 2015. Research and development expense for the nine months ended September 30, 2016 totaled $28.0 million compared to $48.1 million for the same period in 2015.

General and administrative expense for the three months ended September 30, 2016 totaled $3.0 million compared to $2.7 million for the same period in 2015. General and administrative expense for the nine months ended September 30, 2016 totaled $9.4 million compared to $8.0 million for the same period in 2015.

As of September 30, 2016, cash and cash equivalents totaled $69.3.

Upcoming Investor Day

As previously announced, the company will host an Investor Day on Wednesday, December 7, 2016 from 8:00-11:00 a.m. Eastern Time at NASDAQ MarketSite in New York City. A live and archived audio webcast of the Investor Day can be accessed through the Investors section of the company’s website at www.argostherapeutics.com.

Argos’ management will review the scientific, clinical and commercial opportunity behind the company’s lead product candidate, AGS-003, which is currently being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of advanced renal cell carcinoma. Gerald Linette, MD, PhD, chief medical officer for cancer immunotherapy at the University of Pennsylvania Abramson Cancer Center, and Christopher Wood, MD, FACS, professor of urology, division of surgery at the University of Texas MD Anderson Cancer Center will join management in discussing AGS-003 and the treatment landscape.

Third Quarter 2016 Financial Results Conference Call and Webcast Details

Argos management will host a conference call beginning at 8:30 a.m. Eastern Time today to discuss these results and to answer questions.

To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 15427740. A live and archived audio webcast can be accessed through the Investors section of the company’s website at www.argostherapeutics.com. The archived webcast will remain available on the company’s website for twelve (12) months following the call.

About the Arcelis Technology Platform
Arcelis is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient’s individual disease. It is designed to overcome immunosuppression by producing a specifically targeted, durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis process uses only a small disease sample or biopsy as the source of disease-specific antigens, and the patient’s own dendritic cells, which are optimized from cells collected by a leukapheresis procedure. The proprietary process uses RNA isolated from the patient’s disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient’s plasma, and administered via intradermal injection as an individualized immunotherapy.

NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors

On November 14, 2016 NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, reported a presentation of early analysis of the Company’s ongoing Phase II Merkel cell carcinoma study at the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) held November 9-13, 2016, in National Harbor, Maryland (Press release, NantKwest, NOV 14, 2016, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2222275 [SID1234516596]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NantKwest’s presentation on Friday, November 11th, Adoptive Cellular Therapy (ACT) With Allogeneic Activated Natural Killer (aNK) Cells in Patients With Advanced Merkel Cell Carcinoma (MCC): Preliminary Results of a Phase 2 Trial, highlighted interim results from the Company’s ongoing Phase II clinical study of the Company’s investigational aNK natural killer cell therapy in Merkel cell carcinoma. Dr Shailender Bhatia from Fred Hutchinson Cancer Research Center presented the first evidence of a radiological complete response following single agent aNK infusion in a patient with recurrent disease after multiple lines of therapy including relapse after checkpoint inhibitor therapy.

Merkel cell carcinoma is a rare and aggressive skin cancer that is increasing in incidence. Patients with metastatic or locally advanced Merkel cell carcinoma have an extremely poor prognosis with less than 20% of patients surviving longer than five years.

Commenting on the results, Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest, said the following: "We are encouraged to see, even in a heavily pretreated patient population, including patients who have failed checkpoint inhibitor therapy, that our aNK natural killer cell therapy exhibited clinically meaningful antitumor activity, including a promising radiological complete response in one patient, and we look forward to the rapid development of our aNK program in Merkel cell carcinoma. In addition, through our clinical development program, we strive to bring the potential for long-term survival to a broad range of cancer patients in a number of additional cancer indications."

Dr. Soon-Shiong continued, "We believe this data, while a small data set, provides the foundation to submit to the FDA our plans to transition this trial to a pivotal study. Subject to FDA authorization, this transitional study will include our aNK cell therapy in combination with ALT-803, an investigational IL-15 superagonist complex shown to synergistically activate NK and T cells in human clinical trials and currently in development by Altor Biosciences. We believe this novel combination offers the potential to further improve response rates and bring NantKwest’s natural killer cell therapy one step closer to routine clinical cancer care in a patient population in urgent need of better treatment options."

About NantKwest

Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers

On November 14, 2016 Pfizer Inc. (NYSE:PFE) reported that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) (Press release, Pfizer, NOV 14, 2016, View Source [SID1234516593]). As part of the CRADA, Pfizer will collaborate with NCI’s Center for Cancer Research (link is external) (CCR) to arrange and conduct preclinical and clinical trials to evaluate three investigational immunotherapy agents. These include Pfizer’s proprietary immunotherapy agonistic monoclonal antibodies targeting OX40 (CD134), (also known as PF-04518600); and utomilumab, targeting 4-1BB (CD137), (also known as PF-05082566); as well as avelumab, a fully human anti-PD-L1 IgG1 monoclonal antibody (also known as PF-06834635 and MSB0010718C), which is being developed through an alliance between Merck KGaA, Darmstadt, Germany, and Pfizer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaborative preclinical and clinical studies will be co-led by Dr. Jeffrey Schlom, chief of the Laboratory of Tumor Immunology and Biology at CCR, Dr. James Gulley, chief of the Genitourinary Malignancies Branch (link is external) at CCR, and Dr. Chris Boshoff, Senior Vice President and Head of Immuno-oncology, Translational Oncology and Early Development, Pfizer Global Product Development. Under the CRADA, the three investigational immunotherapies will be studied alone, in various combinations with each other, and in combination with standard therapies, such as chemotherapy, radiation and targeted therapies across a range of cancers.

"We are looking forward to combining our expertise with those at the NCI to explore agents targeting the immune system in doublet and triplet combinations. Clinical studies focused on translational endpoints will allow us to optimally develop potential rational combinations," said Chris Boshoff. "The CRADA is an important collaboration for us as we seek to realize the full potential of immunotherapy and hope to ultimately transform the cancer treatment paradigm."

Beyond this collaboration, Pfizer is advancing these and other assets from its growing immuno-oncology portfolio with single agent and novel combination studies, both internally and through other collaborations.

Ignyta Announces Six Upcoming Presentations at the 2016 EORTC-NCI-AACR Annual Meeting

On November 14, 2016 Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, reported six data presentations at the 2016 EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany (Press release, Ignyta, NOV 14, 2016, View Source [SID1234516588]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

One poster presentation will include updated clinical safety and efficacy data from the Phase 1b basket study of RXDX-105, the company’s VEGFR-sparing, potent RET inhibitor.

The company’s data that examine a novel combination of entrectinib — the company’s orally available, CNS-penetrant tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions — with trametinib, designed to overcome drug resistance to TRK inhibition, will be presented as a late-breaking oral plenary presentation.

The company also announced four additional poster presentations related to its robust pipeline of molecularly targeted oncology therapies — entrectinib, RXDX-105, and RXDX-106. These will be the first data Ignyta has disclosed for RXDX-106, and the data presented in the posters highlight both immuno-therapeutic and targeted activity of this novel agent.

"We are excited to provide updated clinical and preclinical data across multiple compounds from our cancer precision medicine pipeline," said Pratik Multani, M.D., Ignyta’s Chief Medical Officer. "In particular, the team is excited to present new clinical data on RXDX-105, and is honored that the ENA Scientific Program Committee has chosen entrectinib for an oral plenary presentation."

Details of the presentations are as follows:

Late-Breaking Oral Plenary Presentation:

Title:
Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside (Abstract number 8LBA)
Presenter: Alexander Drilon, M.D., Memorial Sloan Kettering Cancer Center
Date/Time: Plenary Session 8: Exceptional Response and Expected Resistance

Friday, December 2, 2016, 10:30 am CET

Poster Presentations:

Entrectinib
Title:
Entrectinib, a highly potent pan-Trk, ROS1, and ALK inhibitor, has broad-spectrum, histology-agnostic anti-tumor activity in molecularly defined cancers (Abstract number 78, Poster number P049)
Date/Time: Tuesday, November 29, 2016, 11:45 am – 18:30 pm CET

RXDX-105
Title:
A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors (Abstract number 437, Poster number P116)
Date/Time: Thursday, December 1, 2016, 10:15 am – 17:00 pm CET

Title:
RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes (Abstract number 85, Poster number P056)
Date/Time: Tuesday, November 29, 2016, 11:45 am – 18:30 pm CET

RXDX-106
Title:
Immuno-oncologic efficacy of RXDX-106, a selective, TAM family small molecule kinase inhibitor (Abstract number 65, Poster number P036)
Date/Time: Tuesday, November 29, 2016, 11:45 am – 18:30 pm CET

Title:
RXDX-106 is an orally-available, potent and selective TAM/MET inhibitor demonstrating preclinical efficacy in MET-dependent human malignancies (Abstract number 73, Poster number P044)
Date/Time: Tuesday, November 29, 2016, 11:45 am – 18:30 pm CET

A copy of the presentation and posters will be made available during the sessions in the Scientific Presentations section of the company’s website at View Source, and will be archived and available at that site.